Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis

J. P. Donohue, E. P. Fox, S. D. Williams, Patrick Loehrer, Thomas Ulbright, Lawrence Einhorn, Tess Weathers

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Surgery following chemotherapy for treatment of metastatic testis cancer is reserved for partial remissions with localized tumors considered resectable. After primary chemotherapy, about 90% will have teratoma or necrosis and only 10% will have cancer. The concept of two cycles of post operative chemotherapy in this small group with cancer is supported by a 70% long term cure rate. A more difficult group of patients are those who have had not only primary but also salvage chemotherapy for refractory tumor. About 55% of these patients undergoing post (salvage) chemotherapy RPLND surgery have persistent cancer in the resected specimen. There is no data to support the routine use of repeat salvage chemotherapy post operatively. Of 91 patients presenting for surgery post salvage chemotherapy, 53 were considered completely resected and 36 incompletely resected. Of the 53 realistic candidates for cure with complete resections, 25 were given post operative repeat salvage chemotherapy and 28 received none. 9 (36%) receiving more chemotherapy remained NED and 12 (43%) receiving none remained NED. 12 in each group died of disease. Therefore, there is no data to support routine repeat salvage chemotherapy in patients considered completely resected who had already received salvage chemotherapy pre-operatively. Rather the outcome in this cohort depends more on the completeness of its resectability.

Original languageEnglish
Pages (from-to)190-195
Number of pages6
JournalWorld Journal of Urology
Volume12
Issue number4
DOIs
StatePublished - Aug 1994

Fingerprint

Lymph Node Excision
Drug Therapy
Neoplasms
Teratoma
Testicular Neoplasms
Necrosis

ASJC Scopus subject areas

  • Urology

Cite this

Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection : outcome analysis. / Donohue, J. P.; Fox, E. P.; Williams, S. D.; Loehrer, Patrick; Ulbright, Thomas; Einhorn, Lawrence; Weathers, Tess.

In: World Journal of Urology, Vol. 12, No. 4, 08.1994, p. 190-195.

Research output: Contribution to journalArticle

@article{4017958e79bb4dd5bc7dc62243791ee6,
title = "Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis",
abstract = "Surgery following chemotherapy for treatment of metastatic testis cancer is reserved for partial remissions with localized tumors considered resectable. After primary chemotherapy, about 90{\%} will have teratoma or necrosis and only 10{\%} will have cancer. The concept of two cycles of post operative chemotherapy in this small group with cancer is supported by a 70{\%} long term cure rate. A more difficult group of patients are those who have had not only primary but also salvage chemotherapy for refractory tumor. About 55{\%} of these patients undergoing post (salvage) chemotherapy RPLND surgery have persistent cancer in the resected specimen. There is no data to support the routine use of repeat salvage chemotherapy post operatively. Of 91 patients presenting for surgery post salvage chemotherapy, 53 were considered completely resected and 36 incompletely resected. Of the 53 realistic candidates for cure with complete resections, 25 were given post operative repeat salvage chemotherapy and 28 received none. 9 (36{\%}) receiving more chemotherapy remained NED and 12 (43{\%}) receiving none remained NED. 12 in each group died of disease. Therefore, there is no data to support routine repeat salvage chemotherapy in patients considered completely resected who had already received salvage chemotherapy pre-operatively. Rather the outcome in this cohort depends more on the completeness of its resectability.",
author = "Donohue, {J. P.} and Fox, {E. P.} and Williams, {S. D.} and Patrick Loehrer and Thomas Ulbright and Lawrence Einhorn and Tess Weathers",
year = "1994",
month = "8",
doi = "10.1007/BF00185671",
language = "English",
volume = "12",
pages = "190--195",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection

T2 - outcome analysis

AU - Donohue, J. P.

AU - Fox, E. P.

AU - Williams, S. D.

AU - Loehrer, Patrick

AU - Ulbright, Thomas

AU - Einhorn, Lawrence

AU - Weathers, Tess

PY - 1994/8

Y1 - 1994/8

N2 - Surgery following chemotherapy for treatment of metastatic testis cancer is reserved for partial remissions with localized tumors considered resectable. After primary chemotherapy, about 90% will have teratoma or necrosis and only 10% will have cancer. The concept of two cycles of post operative chemotherapy in this small group with cancer is supported by a 70% long term cure rate. A more difficult group of patients are those who have had not only primary but also salvage chemotherapy for refractory tumor. About 55% of these patients undergoing post (salvage) chemotherapy RPLND surgery have persistent cancer in the resected specimen. There is no data to support the routine use of repeat salvage chemotherapy post operatively. Of 91 patients presenting for surgery post salvage chemotherapy, 53 were considered completely resected and 36 incompletely resected. Of the 53 realistic candidates for cure with complete resections, 25 were given post operative repeat salvage chemotherapy and 28 received none. 9 (36%) receiving more chemotherapy remained NED and 12 (43%) receiving none remained NED. 12 in each group died of disease. Therefore, there is no data to support routine repeat salvage chemotherapy in patients considered completely resected who had already received salvage chemotherapy pre-operatively. Rather the outcome in this cohort depends more on the completeness of its resectability.

AB - Surgery following chemotherapy for treatment of metastatic testis cancer is reserved for partial remissions with localized tumors considered resectable. After primary chemotherapy, about 90% will have teratoma or necrosis and only 10% will have cancer. The concept of two cycles of post operative chemotherapy in this small group with cancer is supported by a 70% long term cure rate. A more difficult group of patients are those who have had not only primary but also salvage chemotherapy for refractory tumor. About 55% of these patients undergoing post (salvage) chemotherapy RPLND surgery have persistent cancer in the resected specimen. There is no data to support the routine use of repeat salvage chemotherapy post operatively. Of 91 patients presenting for surgery post salvage chemotherapy, 53 were considered completely resected and 36 incompletely resected. Of the 53 realistic candidates for cure with complete resections, 25 were given post operative repeat salvage chemotherapy and 28 received none. 9 (36%) receiving more chemotherapy remained NED and 12 (43%) receiving none remained NED. 12 in each group died of disease. Therefore, there is no data to support routine repeat salvage chemotherapy in patients considered completely resected who had already received salvage chemotherapy pre-operatively. Rather the outcome in this cohort depends more on the completeness of its resectability.

UR - http://www.scopus.com/inward/record.url?scp=0028709621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028709621&partnerID=8YFLogxK

U2 - 10.1007/BF00185671

DO - 10.1007/BF00185671

M3 - Article

C2 - 7820140

AN - SCOPUS:0028709621

VL - 12

SP - 190

EP - 195

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 4

ER -